Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
McKesson
Fuji
UBS
Johnson and Johnson
Dow
Baxter
US Army

Generated: May 20, 2018

DrugPatentWatch Database Preview

HIBICLENS Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Hibiclens patents expire, and what generic alternatives are available?

Hibiclens is a drug marketed by Molnlycke Hlth and is included in two NDAs.

The generic ingredient in HIBICLENS is chlorhexidine gluconate. There are fifty-seven drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the chlorhexidine gluconate profile page.
Drug patent expirations by year for HIBICLENS
Medical Subject Heading (MeSH) Categories for HIBICLENS
Synonyms for HIBICLENS
(1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylene]amino]methylene]amino]hexyl]-1-[amino-(4-chloroanilino)methylene]guanidine; (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid
1-(4-chlorophenyl)-3-[N-[6-[[N-[N-(4-chlorophenyl)carbamimidoyl]carbamimidoyl]amino]hexyl]carbamimidoyl]guanidine; (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide), digluconate
1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide] Digluconate
1,6-Bis(N5-[p-chlorophenyl]-N1-biguanido)hexane; 1,1 inverted exclamation marka-Hexamethylenebis(5-[p-chlorophenyl]biguanide)
1,6-Bis(N5-[p-chlorophenyl]-N1-biguanido)hexane; 1,1'-Hexamethylenebis(5-[p-chlorophenyl]biguanide)
105791-72-8
12068-31-4
124973-71-3
14007-07-9
150621-85-5
151498-43-0
18472-51-0
2,4,11,13-Tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-, digluconate
21293-24-3
227749-99-7
230296-52-3
23289-58-9
40330-16-3
452971-25-4
51365-13-0
52196-45-9
52387-19-6
60042-57-1
60404-86-6
82432-16-4
906339-38-6
Abacil
AKOS015896303
AKOS025310696
AN-18792
Arlacide G
Bioscrub
Brian Care
C08038
CHEBI:28312
Chlorhexidin glukonatu
Chlorhexidine D-digluconate
Chlorhexidine di-D-gluconate
CHLORHEXIDINE DIGLUCONATE
Chlorhexidine digluconate solution
Chlorhexidine digluconate solution, 20% in H2O
Chlorhexidine digluconate, 20% w/v aqueous solution
Chlorhexidine digluconate, pharmaceutical secondary standard; traceable to USP and PhEur
Chlorhexidine gluconate
Chlorhexidine gluconate (JP17/USP)
Chlorhexidine gluconate [USAN:USP:JAN]
Chx plus concentrate premium chlorhexidine teat dip concentrate
Cida-Stat
D-Gluconic acid, compd with N,N''-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide (2:1)
D-Gluconic acid, compd. with N,N''-bis(4-chlorophenyl) -3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide (2:1)
D-Gluconic acid, compd. with N1,N14-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide (2:1)
D00858
DTXSID5034519
Dyna-hex
EC 242-354-0
Exidine
Fight bac
Gluconic acid, compd. with 1,1'-hexamethylene bis(5-(p-chlorophenyl)biguanide) (2:1), D- (8CI)
Hibiclens (TN)
Hibidil
Hibiscrub
Hibitane
Hibitane gluconate
I06-2074
J-011837
Kleersight
M166
MFCD00083599
Microderm
MolPort-006-069-426
MOR84MUD8E
N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]--D-gluconic acid (1/2)
Peridex
Peridex (TN)
Periochip
Periogard
Periogard (TN)
Pharmaseal Scrub Care
pHiso-Med
Prevacare
Prevacare R
SCHEMBL34468
Steri-Stat
UNII-MOR84MUD8E
Unisept

US Patents and Regulatory Information for HIBICLENS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SOLUTION;TOPICAL 017768-001 Approved Prior to Jan 1, 1982 OTC Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SPONGE;TOPICAL 018423-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for HIBICLENS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SPONGE;TOPICAL 018423-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SOLUTION;TOPICAL 017768-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SPONGE;TOPICAL 018423-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Molnlycke Hlth HIBICLENS chlorhexidine gluconate SOLUTION;TOPICAL 017768-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
US Army
Chubb
Moodys
Federal Trade Commission
US Department of Justice
Deloitte
Boehringer Ingelheim
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.